REPL
Replimune Group, Inc.
NASDAQ · USHealthcareBiotechnology
$10.51+2.74%
Price as of Jul 20, 2026
REPL capital
Replimune Group, Inc. capital & dividend
Leverage, liquidity, debt coverage and shareholder-distribution metrics.
Leverage
- Debt / equity
- 0.67x
- Net debt / equity
- -0.59x
- Debt / assets
- 0.34x
- Debt / EBITDA
- -0.35x
- Net debt / EBITDA
- 0.31x
Liquidity & coverage
- Current ratio
- 4.79x
- Quick ratio
- 4.79x
- Cash ratio
- 4.62x
- Interest coverage
- -36.11x
- EBITDA / interest
- -35.50x
- Working capital
- $220.9M
Cash & dividend
- FCF / debt
- -2.55x
- Cash flow / debt
- -2.51x
- Dividend per share
- —
- Dividend yield
- —
- Dividend growth 1y
- —
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.